Scynexis SCYX
NASDAQ SCYX
$4.91 -0.24 (-4.66%)
At close: Sep 9, 2026 · 4:00 PM EDT

Scynexis (SCYX) Cash from Operations (2013 - 2026)

Scynexis' (SCYX) quarterly Cash from Operations came in at -$14.9 million in Q2 2026, down 98.6% on a YoY basis from -$1.1 billion in Q2 2025, and down 83.74% quarter-over-quarter from -$8.1 million in Q1 2026.

Analysis

Scynexis (SCYX) Cash from Operations (2013 - 2026) Analysis & Trends

Scynexis (SCYX) has reported Cash from Operations for 14 consecutive years, with -$14.9 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Cash from Operations fell 98.6% year-over-year to -$14.9 million; the trailing twelve-month figure through Jun 2026 stood at -$13.3 million (up 44.78% YoY), and the FY2025 full-year result was -$5.3 million, up 78.0% from the prior year.
  • Cash from Operations slipped to -$14.9 million in Q2 2026 per SCYX's latest filing, from -$8.1 million in the prior quarter.
  • Across five years, Cash from Operations topped out at $74.4 million in Q2 2023 and bottomed at -$22.8 million in Q4 2022.
  • Historically, Cash from Operations has averaged -$4.0 million across 5 years, with a median of -$8.4 million in 2025.
  • The sharpest annual moves came in 2022 and 2023: Cash from Operations tumbled 2006.46% in 2022, then soared 500.4% in 2023.
  • Over 5 years, Cash from Operations stood at -$22.8 million in 2022, then soared by 66.08% to -$7.7 million in 2023, then dropped by 28.08% to -$9.9 million in 2024, then soared by 285.74% to $18.4 million in 2025, then sank by 180.89% to -$14.9 million in 2026.
  • According to Business Quant data, Cash from Operations over the past three periods registered -$14.9 million, -$8.1 million, and $18.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Operations (Qtr)
1 Amgen 211.73 Bn 197.74 Bn 7.24 Bn 4.00 Bn
2 Gilead Sciences 180.92 Bn 177.74 Bn 6.22 Bn 3.57 Bn
3 Vertex Pharmaceuticals 132.16 Bn 124.30 Bn 2.84 Bn 1.13 Bn
4 Regeneron Pharmaceuticals 82.89 Bn 74.90 Bn 3.93 Bn 813.00 Mn
5 Argenx Se 61.41 Bn 56.23 Bn 1.37 Bn -
6 Moderna 53.99 Bn 48.85 Bn 52.00 Mn -526.00 Mn
7 Alnylam Pharmaceuticals 34.48 Bn 31.18 Bn 992.69 Mn 326.72 Mn
8 Biogen 31.15 Bn 29.86 Bn 1.96 Bn 448.90 Mn
9 Roivant Sciences 30.05 Bn 30.05 Bn 1.16 Mn -270.50 Mn
10 Scynexis 58.41 Mn -56.29 Mn - -14.89 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -14.89 Mn
Mar 31, 2026 -8.10 Mn
Dec 31, 2025 18.40 Mn
Sep 30, 2025 -8.72 Mn
Jun 30, 2025 -7.50 Mn
Mar 31, 2025 -7.47 Mn
Dec 31, 2024 -9.91 Mn
Sep 30, 2024 765,000.00
Jun 30, 2024 -10.86 Mn
Mar 31, 2024 -4.01 Mn
Dec 31, 2023 -7.74 Mn
Sep 30, 2023 12.42 Mn
Jun 30, 2023 74.40 Mn
Mar 31, 2023 -18.92 Mn
Dec 31, 2022 -22.81 Mn
Sep 30, 2022 -22.51 Mn
Jun 30, 2022 -18.58 Mn
Mar 31, 2022 -15.99 Mn
Dec 31, 2021 -25.52 Mn
Sep 30, 2021 -16.59 Mn